Analyzing Language, Improving Health

Try our interactive demo below:

Please take 30 seconds to describe your day today from start to finish.

Please wait while your sample uploads...

For Patients

Subscribe monthly to analyze your health proactively and improve your health.

For Providers

Lower per capita health costs and improve health outcomes from on-premise deployments of our mobile app.

For Pharma

Build companion diagnostics for your drug portfolio.

For Researchers

Amend your IRB to collect speech data with our API and co-publish research papers with us.

About Us

We empower patients with tools to measure their overall health through collecting and analyzing speech samples. By fingerprinting health abnormalities early, we equip patients and physicians with insight to prevent symptoms from worsening. In this way, we strive to be the world's leading platform company to advance linguistics as a tool to characterize various health conditions.

In the Press

Our Mission

We believe the next-generation of medicine will be personalized, quality-driven, and focused on prevention. We place your health at your fingertips through our linguistic biomarker assays.

Areas of Focus


Depression affects up to 20% of the population in a given year. The DepLex assay, currently used in a research context, is being built to output whether or not someone is likely depressed from frequency, speaking rate, and a cluster of semantic features.


Individuals who develop schizophrenia often have a multi-year period prior to their first episode of psychosis called the "prodrome." This period is marked by anxiety, depression, social isolation and subtle disorganization in thoughts. Our PsychLex assay characterizes these changes and predicts which individuals will have onset of psychosis and which will not.

Alzheimer’s Disease

Alzheimer’s disease (AD) is a progressive degenerative disease characterized by a gradual decline in memory. This leads to changes in speech, like pauses in language. Our AlzLex assay can detect AD symptoms early and characterize memory decline as AD progresses.

Parkinson’s Disease

Parkinson’s disease (PD) often goes undiagnosed until motor tremors appear in patients. Our ParkLex assay captures abnormalities in the vocal fold and syntax of speech (polarity estimators) to log PD symptoms early and track PD progression.

We are actively seeking investors, partnerships, and R&D pilots.

Let us know how we can work together!

-----> Download Our Factsheet <-----
Neurolex Laboratories Inc.

Atlanta - Austin - Boston - New York - San Francisco.

Federal Solutions

TIN: 81-4970682
DUNS: 080568313
CAGE Code: 7UB09
541720 Language R&D services
Psychology R&D services
Cognitive R&D services
541712 Medical R&D laboratories or services
Health R&D laboratories or services